Lotus Pharmaceutical Co., Ltd. (TPE:1795)

Lotus Pharmaceutical Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	-	6,030	1,771	1,983	1,605	1,489
Cash & Short-Term Investments	6,030	6,030	1,771	1,983	1,605	1,489
Cash Growth	93.19%	240.51%	-10.71%	23.54%	7.82%	16.61%
Accounts Receivable	-	7,435	6,384	4,651	3,266	2,747
Other Receivables	-	268.54	233.13	276.24	141.56	53.19
Receivables	-	7,703	6,617	4,927	3,407	2,801
Inventory	-	3,833	3,775	3,330	3,073	2,208
Other Current Assets	-	531.5	489.37	420.4	247.24	284.61
Total Current Assets	-	18,098	12,653	10,661	8,333	6,783
Property, Plant & Equipment	-	3,666	3,511	3,148	2,642	2,305
Long-Term Investments	-	3,594	3,048	2,158	301.73	412.85
Goodwill	-	6,127	5,670	5,668	5,586	5,896
Other Intangible Assets	-	5,199	5,487	5,910	2,971	3,177
Long-Term Accounts Receivable	-	122.73	152.6	-	-	-
Long-Term Deferred Tax Assets	-	486.42	411.69	390.12	310.82	364.61
Long-Term Deferred Charges	-	2,639	1,878	1,406	891.98	654.1
Other Long-Term Assets	-	168.74	180.28	185.33	185.35	161.12
Total Assets	-	40,101	32,992	29,526	21,222	19,753
Accounts Payable	-	1,070	670.8	1,403	747.55	1,732
Accrued Expenses	-	-	3.06	3.57	0.93	2.46
Short-Term Debt	-	1,615	510	155.92	1,377	410
Current Portion of Long-Term Debt	-	3,390	1,303	59.95	794.9	1,359
Current Portion of Leases	-	84.32	70.24	58.99	62.47	40.43
Current Income Taxes Payable	-	664.47	436.56	731.15	280.16	226.62
Current Unearned Revenue	-	180.9	132.85	183.08	132.01	132.1
Other Current Liabilities	-	1,433	1,398	3,297	931.26	980.66
Total Current Liabilities	-	8,438	4,524	5,893	4,326	4,883
Long-Term Debt	-	8,384	9,519	8,596	4,667	4,948
Long-Term Leases	-	194.06	182.2	46.82	43.41	76.58
Long-Term Unearned Revenue	-	26.56	45.33	65.92	85.96	111.78
Long-Term Deferred Tax Liabilities	-	1,093	721.2	448.4	304.15	144.69
Other Long-Term Liabilities	-	112.17	162.29	235.84	224.03	257.46
Total Liabilities	-	18,921	15,658	15,658	10,153	11,008
Common Stock	-	2,659	2,650	2,626	2,628	2,454
Additional Paid-In Capital	-	7,431	7,131	7,534	8,039	6,799
Retained Earnings	-	12,660	8,900	4,823	1,701	353.66
Treasury Stock	-	-48.39	-51.1	-57.35	-57.75	-
Comprehensive Income & Other	-	-1,521	-1,295	-1,058	-1,241	-860.97
Total Common Equity	21,180	21,180	17,334	13,868	11,069	8,745
Shareholders' Equity	21,180	21,180	17,334	13,868	11,069	8,745
Total Liabilities & Equity	-	40,101	32,992	29,526	21,222	19,753
Total Debt	13,667	13,667	11,585	8,918	6,944	6,834
Net Cash (Debt)	-7,636	-7,636	-9,814	-6,935	-5,339	-5,345
Net Cash Per Share	-28.97	-28.99	-37.45	-26.50	-20.80	-21.95
Filing Date Shares Outstanding	262.34	265.39	264.47	262.04	262.25	245.35
Total Common Shares Outstanding	262.34	265.39	264.47	262.04	262.25	245.35
Working Capital	-	9,660	8,129	4,768	4,007	1,900
Book Value Per Share	79.81	79.81	65.54	52.92	42.21	35.64
Tangible Book Value	9,855	9,855	6,177	2,291	2,512	-327.16
Tangible Book Value Per Share	37.13	37.13	23.36	8.74	9.58	-1.33
Land	-	599.33	622.55	622.31	615.49	654.22
Buildings	-	2,074	1,888	1,384	1,313	1,012
Machinery	-	1,865	1,826	1,547	1,408	1,324
Construction In Progress	-	706.38	639.41	1,077	675.22	608.86
Leasehold Improvements	-	100.15	71.01	87.87	78.26	85.33

Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.